NYSE · Health care

Impact Biomedical Inc. (IBO)

At June 30, 2026 it held $10K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.

Watch IBO in 60 seconds

Price

$4.30

-0.69% on the day · November 10, 2026

52-week range $2.43 to $10.51

Market cap

$463.6M

Key facts about Impact Biomedical Inc.

Net worth: Impact Biomedical Inc. has a market value (market cap) of $463.6M at the latest share price, and shareholders' equity of $10.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Revenue and profit: In fiscal 2025 revenue was $32K (-36.0% year on year), with a net loss of $11.8M.
Cash flow: In fiscal 2025 operations used $1.9M of cash.
Latest report: The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 7, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
Next earnings report: Impact Biomedical Inc.'s next report was expected around November 6, 2026 and is not on file with the SEC yet.

What Impact Biomedical Inc. does

Impact Biomedical Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker IBO.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$32K	-$4.3M	-$11.8M	-$0.38	n/a
2024	n/a	-$28.8M	-$24.7M	-$2.30	n/a
2023	n/a	-$4M	-$4.3M	-$0.07	n/a
2023	$50K	-$3.4M	-$7.3M	-$0.10	n/a

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

A report was expected around November 6, 2026 and is not on file yet.

Estimated from its filing rhythm: 52 weeks after its report of November 7, 2025. Not a date the company has announced. See the report calendar · Earnings, quarter by quarter

Where IBO ranks in Health care

Revenue$32K

#731 of 751 in Health care · Bottom 3%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Impact Biomedical Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 17, 2026
Form 425 filing 425
September 17, 2026
Investor disclosure 8-K
September 15, 2026
Form 425 filing 425
September 15, 2026
Investor disclosure 8-K
August 7, 2026
Quarterly report 10-Q · period to June 30, 2026Revenue fell 57% to $3K versus the same quarter last year; diluted EPS -$0.01 versus -$1.18.
May 12, 2026
Quarterly report 10-Q · period to March 31, 2026Revenue was $7K; diluted EPS -$0.02 versus -$0.11.
April 22, 2026
Form S-8 POS filing S-8 POS
April 6, 2026
Form S-8 POS filing S-8 POS
March 11, 2026
Annual report 10-K · period to December 31, 2025Revenue was $32K; diluted EPS -$0.38 versus -$2.30.
March 4, 2026
Material agreement 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 24, 2026. Insider transactions on SEC

Insider trades

What the people running Impact Biomedical Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $1.7K worth of shares in the last 90 days and bought none on the open market.

Bought (open market)

last 90 days

Sold

$1.7K

last 90 days

Net sold

906

$1.7K

Date	Insider	What	Shares	Price	Value	Filing
September 24, 2026	Dss, Inc.10% owner	Sold	156	$7.06	$1.1K	Form 4
September 23, 2026	Dss, Inc.10% owner	Sold	27	$6.95	$187.7	Form 4
September 22, 2026	Dss, Inc.10% owner	Sold	723	$0.55	$397.7	Form 4
March 27, 2026	Macko Todd DChief Financial Officer	Sold	43,400	$0.56	$24.4K	Form 4
March 25, 2026	Macko Todd DChief Financial Officer	Sold	1,600	$0.60	$961.3	Form 4
March 23, 2026	Grady JasonDirector	Sold	50,000	$0.65	$32.5K	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns IBO

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

No holder of 5% or more has filed about this company in that window.

Latest filings below 5%: Heng Fai Ambrose Chan 2.9% (April 4, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

3 insiders reported holding 994,822 shares in total, about $4.3M at the last price.

Holder	Shares	As of
Dss, Inc.10% owner	589,518	September 24, 2026
Grady JasonDirector	250,182	March 23, 2026
Macko Todd DChief Financial Officer	155,122	March 27, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about IBO

What does Impact Biomedical Inc. do?

Impact Biomedical Inc. is a company in the Health care sector, listed on NYSE as IBO. Its shares trade on NYSE under the ticker IBO.

What is Impact Biomedical Inc.'s net worth?

Impact Biomedical Inc. has a market value (market cap) of $463.6M at the latest share price, and shareholders' equity of $10.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Impact Biomedical Inc. profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $789K.

When did Impact Biomedical Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 24, 2026.

When is Impact Biomedical Inc.'s next earnings report?

Impact Biomedical Inc.'s next report was expected around November 6, 2026 and is not on file with the SEC yet.

Similar companies

PRTA

Prothena Corp Public Ltd Co

PBYI

Puma Biotechnology, Inc.

Eupraxia Pharmaceuticals Inc.

Compare IBO with

Compare IBO with any company

Follow IBO

Get an email when Impact Biomedical Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Where the numbers come from

Financial figures are the values Impact Biomedical Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.